EUVIMEDEUVIMED entdecken
Crossref

Cytokines as prognostic biomarkers in pulmonary arterial hypertension

Athénaïs Boucly iD, Ly Tu, Christophe Guignabert iD, Christopher Rhodes, Pascal De Groote, Grégoire Prévot, Emmanuel Bergot, Arnaud Bourdin iD, Antoine Beurnier iD, Anne Roche, Mitja Jevnikar, Xavier Jaïs und 5 weitere

European Respiratory Journal · 2023-03 · 61 (3) · 2201232

DOI: 10.1183/13993003.01232-2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 22.12.2022. Verfasst von Athénaïs Boucly und 16 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR_S999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: British Heart Foundation, Projet Hospitalier de Recherche Clinique, Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH) are challenged by the lack of accurate disease-specific and prognostic biomarkers. To date, brain natriuretic peptide (BNP) and/or its N-terminal fragment (NT-proBNP) are the only markers for right ventricular dysfunction used in clinical practice, in association with echocardiographic and invasive haemodynamic variables to predict outcome in patients with PAH.

Methods

This study was designed to identify an easily measurable biomarker panel in the serum of 80 well-phenotyped PAH patients with idiopathic, heritable or drug-induced PAH at baseline and at first follow-up. The prognostic value of identified cytokines of interest was secondly analysed in an external validation cohort of 125 PAH patients.

Results

Among the 20 biomarkers studied with the multiplex Ella platform, we identified a three-biomarker panel composed of β-NGF, CXCL9 and TRAIL that were independently associated with prognosis both at the time of PAH diagnosis and at the first follow-up after initiation of PAH therapy. β-NGF and CXCL9 were predictors of death or transplantation, whereas high levels of TRAIL were associated with a better prognosis. Furthermore, the prognostic value of the three cytokines was more powerful for predicting survival than usual non-invasive variables (New York Heart Association Functional Class, 6-min walk distance and BNP/NT-proBNP). The results were validated in a fully independent external validation cohort.

Conclusion

The monitoring of β-NGF, CXCL9 and TRAIL levels in serum should be considered in the management and treatment of patients with PAH to objectively guide therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionHypertension, PulmonaryHumansPrognosisCytokinesFamilial Primary Pulmonary HypertensionBiomarkersNatriuretic Peptide, BrainPeptide Fragments

Substanzen

CytokinesBiomarkersNatriuretic Peptide, BrainPeptide Fragments

Autor:innen und Institutionen

  • INSERM UMR_S999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • AP-HP, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Université de Lille, Service de Cardiologie, CHU Lille, Institut Pasteur de Lille, Inserm U1167, Lille, France.
  • CHU de Toulouse, Hôpital Larrey, Service de Pneumologie, Toulouse, France.

ORCID-Profile: Athénaïs Boucly, Christophe Guignabert, Arnaud Bourdin, Antoine Beurnier, David Montani, Martin R Wilkins, Marc Humbert, Olivier Sitbon, Laurent Savale

Förderung

  • British Heart Foundation
  • Projet Hospitalier de Recherche Clinique
  • Agence Nationale de la Recherche
  • Institut National de la Santé et de la Recherche Médicale

Zitieren

APA

Boucly, A., Tu, L., Guignabert, C., Rhodes, C., De Groote, P., Prévot, G., Bergot, E., Bourdin, A., Beurnier, A., Roche, A., Jevnikar, M., Jaïs, X., Montani, D., Wilkins, M. R., Humbert, M., Sitbon, O., & Savale, L. (2023). Cytokines as prognostic biomarkers in pulmonary arterial hypertension. European Respiratory Journal, 61(3), 2201232. https://doi.org/10.1183/13993003.01232-2022

Vancouver

Boucly A, Tu L, Guignabert C, Rhodes C, De Groote P, Prévot G, et al. Cytokines as prognostic biomarkers in pulmonary arterial hypertension. European Respiratory Journal. 2023;61(3):2201232. doi:10.1183/13993003.01232-2022

BibTeX
@article{Boucly2023,
  author = {Boucly, Athénaïs and Tu, Ly and Guignabert, Christophe and Rhodes, Christopher and De Groote, Pascal and Prévot, Grégoire and Bergot, Emmanuel and Bourdin, Arnaud and Beurnier, Antoine and Roche, Anne and Jevnikar, Mitja and Jaïs, Xavier and Montani, David and Wilkins, Martin R and Humbert, Marc and Sitbon, Olivier and Savale, Laurent},
  title = {Cytokines as prognostic biomarkers in pulmonary arterial hypertension},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {61},
  number = {3},
  pages = {2201232},
  doi = {10.1183/13993003.01232-2022}
}
Kostenlos starten →